Pay in 4 interest-free payments of $25.50 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
2018 Jan-Feb
Ciraparantag
74(6):897-905
Compared with placebo-treated animals
DMU-2105 showed a very high level of selectivity towards CYP1B1 with respect to the IC50 values obtained with CYP1A1
AZD-9291 mesylate Size:Solid 10 mg 2018 Jan-FebOsimertinib, also known as AZD 9291 and Mereletinib, is a third generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors. AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin
US$ 18.00
US$ 19.00
US$ 27.20
US$ 295.00
US$ 30.00
US$ 122.00